Mablink Bioscience, a biotechnology company that focuses on advancing next-generation antibody-drug conjugates (ADCs) through its proprietary PSARLink™ platform, has announced its acquisition by Eli Lilly and Company. The PSARLink™ technology, featuring an innovative hydrophilic linker using a polysarcosine arm, offers the potential to expand the therapeutic benefits of ADCs, thus maximizing their therapeutic effectiveness.

Jean-Guillaume Lafay, Mablink's CEO, expressed his enthusiasm about the acquisition, emphasizing that it signifies strong support for their approach, technology, and team. The alignment of values between Mablink and Lilly, combined with their collective expertise, presents a unique opportunity to harness Mablink's capabilities and initiatives, with the ultimate goal of developing groundbreaking therapies for cancer patients with significant unmet medical needs. Lafay also extended gratitude to all those who have contributed to Mablink's growth and progress since its inception.

It is important to note that this transaction is contingent on approval from the French Ministry of the Economy.

PSARLink™ linkers serve as chemical and physical connectors between an antibody and a selected cytotoxic molecule, facilitating the targeted delivery of the payload to tumor cells. The unique structure of PSARLink™ effectively conceals cytotoxic molecules, particularly hydrophobic compounds, allowing them to circulate in the body for extended periods, thereby enhancing their efficacy in eliminating tumor cells. PSARLink™-based ADCs have also demonstrated an enhanced therapeutic index in animal models.

 

Source: globenewswire.com

Report Abuse